MITIGO Drug Patent Profile
Which patents cover Mitigo, and what generic alternatives are available?
Mitigo is a drug marketed by Piramal Critical and is included in one NDA.
The generic ingredient in MITIGO is morphine sulfate. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mitigo
A generic version of MITIGO was approved as morphine sulfate by HOSPIRA on September 30th, 1992.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MITIGO?
- What are the global sales for MITIGO?
- What is Average Wholesale Price for MITIGO?
Summary for MITIGO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 3,941 |
| Drug Prices: | Drug price information for MITIGO |
| DailyMed Link: | MITIGO at DailyMed |
Pharmacology for MITIGO
| Drug Class | Opioid Agonist |
| Mechanism of Action | Full Opioid Agonists |
US Patents and Regulatory Information for MITIGO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Piramal Critical | MITIGO | morphine sulfate | INJECTABLE;INJECTION | 204393-001 | Jul 16, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Piramal Critical | MITIGO | morphine sulfate | INJECTABLE;INJECTION | 204393-002 | Jul 16, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
